Keywords: Euroe, EMA, CHMP, Gilenya, Halaven, Jevtana, Pravafenix, Trobalt, Fampyra, Multaq, Eisai, Sanofi-Aventis, Labs SMB, GlaxoSmithKline, Merck KGaA, Biogen Idec, Meda
EMA advisory committee backs Gilenya, Halaven, Jevtana, Pravafenix and Trobalt, but negatives for Fampyra and Multaq
Article | 24 January 2011
The European Medicines Agency’s advisory body, the Committee the Committee for Medicinal Products for Human Use (CHMP), at ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
